OncoMutational ratio on ctDNA: A potential novel biomarker in NSCLC

被引：0

作者：

Ambrosini, P. ^{[1
]}

Provenzano, L. ^{[1
]}

Bottiglieri, A. ^{[1
]}

Spagnoletti, A. ^{[1
]}

Di Guida, G. ^{[2
]}

Mazzeo, L. ^{[1
]}

Beninato, T. ^{[1
]}

Leporati, R. ^{[3
]}

Occhipinti, M. ^{[4
]}

Brambilla, M. ^{[1
]}

Manglaviti, S. ^{[1
]}

Ganzinelli, M. ^{[4
]}

Miskovic, V. ^{[5
]}

Proto, C. ^{[1
]}

Dumitrascu, A. D. ^{[1
]}

De Braud, F. G. M. ^{[6
]}

Della Corte, C. M. ^{[7
]}

Lo Russo, G. ^{[8
]}

Viscardi, G. ^{[9
]}

Prelaj, A. ^{[10
]}

机构：

[1] Fdn IRCCS Ist Nazl Tumori, Med Oncol Dept, Milan, Italy

[2] Univ Campania Luigi Vanvitelli, Med Oncol Dept, Caserta, Italy

[3] Ist Nazl Tumori Milano Fdn IRCCS, Oncol Dept, Milan, Italy

[4] Fdn IRCCS Ist Nazl Tumori, Milan, Italy

[5] Politecn Milan, Dipartimento Elettron Informaz & Bioingegneria, Milan, Italy

[6] Fdn IRCCS Ist Nazl Tumori, Med Oncol & Haematol Dept, Milan, Italy

[7] Univ Campania Luigi Vanvitelli, Dipartimento Oncol, Naples, Italy

[8] Fdn IRCCS Ist Nazl Tumori, Dipartimento Oncol Toraco Polmonare, Milan, Italy

[9] Univ Campania Luigi Vanvitelli, Dipartimento Oncol Medica, Naples, Italy

[10] Fdn IRCCS Ist Nazl Tumori, Oncol Medica Torac Dept, Milan, Italy

来源：

JOURNAL OF THORACIC ONCOLOGY | 2023年 / 18卷 / 04期

关键词：

D O I：

暂无

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

68P

引用

页码：S79 / S80

页数：2

共 50 条

[1] Circulating tumor DNA (ctDNA) as predictive biomarker in NSCLC patients treated with nivolumab
Passiglia, F.
Perez, A.
Listi, A.
Castiglia, M.
Musso, E.
Ancona, C.
Rizzo, S.
Alu, M.
Blasi, L.
Russo, A.
ANNALS OF ONCOLOGY, 2017, 28
[2] Dynamics of ctDNA in patients with NSCLC
Zhabina, A. S.
Mjslik, A.
Moiseenko, F.
Moiseenko, V.
Stepanova, M.
ANNALS OF ONCOLOGY, 2019, 30
[3] Plasma ctDNA dynamics as clinical response biomarker for NSCLC: A systematic review and meta-analysis
Leite, L. F.
Saldanha, E. F.
Halamy, L.
de Menezes, J. S. A.
Buonopane, I. R.
Braganca dos Santos, J. A.
de Menezes, C. U.
Lopes, G.
ANNALS OF ONCOLOGY, 2024, 35 : S256 - S256
[4] ctDNA Positivity Is a Clinical Prognosis Biomarker in Patients with EGFR ex20ins+NSCLC
Chatterjee, S.
Tong, X.
Su, Z.
Li, Y.
Guha, M.
Churchill, E. N.
Fram, R. J.
Vincent, S.
JOURNAL OF THORACIC ONCOLOGY, 2023, 18 (11) : S255 - S255
[5] Circulating Tumor DNA (ctDNA) Clearance as a Biomarker in Patients With Locally Advanced NSCLC Following Chemoradiation
Knapp, B.
Mezquita, L.
Devarakonda, S.
Aldea, M.
Waqar, S.
Pepin, K.
Ward, J.
Botticella, A.
Howarth, K.
Knape, C.
Morris, C.
Govindan, R.
Besse, B.
Morgensztern, D.
JOURNAL OF THORACIC ONCOLOGY, 2021, 16 (03) : S208 - S208
[6] Validity of Serum Zinc/Copper Ratio as a Potential Novel Biomarker in Childhood Epilepsy
Bakri, Ali H.
Meki, Abdel-Raheim M. A.
Nassar, Ahmed Y.
Hassan, Mohammed H.
Ellisy, Reham A. M.
Radwan, Eman
Ameen, Hesham H.
Nasser, Shimaa A.
Abd-Elmawgood, Eman A.
CLINICAL LABORATORY, 2023, 69 (11) : 2341 - 2350
[7] Extracellular vesicle DNA as a potential biomarker for cancer detection: A comparative analysis with ctDNA
Wu, Tad
Tsering, Thupten
Chen, Yunxi
Nadeau, Amelie
Burnier, Julia V.
CANCER RESEARCH, 2024, 84 (06)
[8] A novel microRNA signature associated with cisplatin resistant NSCLC holds both diagnostic and prognostic biomarker potential
MacDonagh, L.
Gray, S. G.
Cuffe, S.
Finn, S. P.
Young, V.
Ryan, R.
Nicholson, S.
Leonard, N.
Sui, J. Sze Yin
O'Byrne, K. J.
Barr, M. P.
LUNG CANCER, 2016, 91 : S2 - S3
[9] ctDNA-adjusted bTMB as a predictive biomarker for patients with NSCLC treated with PD-(L)1 inhibitors
Wei Nie
Zhi-Jie Wang
Kai Zhang
Bing Li
Yi-Ran Cai
Feng-Cai Wen
Ding Zhang
Yue-Zong Bai
Xue-Yan Zhang
Shu-Yuan Wang
Lei Cheng
Hua Zhong
Li Liu
Jie Wang
Bao-Hui Han
BMC Medicine, 20
[10] IRF4: A potential prognostic biomarker for immunotherapy in NSCLC
Zhao, Qian
Li, Butuo
Xu, Yiyue
Li, Xuanzong
Yu, Jinming
Wang, Linlin
INTERNATIONAL IMMUNOPHARMACOLOGY, 2024, 143

← 1 2 3 4 5 →